CTOs on the Move

Castle Biosciences

www.castlebiosciences.com

 
Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat glioblastoma, uveal melanoma, low grade gliomas. We anticipate tests for thymoma and esophageal cancer to be on the market in the near future (1Q-1H, 2012) as they are going through final validation.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Castle Biosciences raised $11.7M on 07/27/2015
Castle Biosciences raised $12M on 04/18/2019

Similar Companies

Genemed Synthesis

Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Operon Biotechnologies

Operon Biotechnologies, Inc is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nova Biologics.

Nova Biologics. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Esker Therapeutics

We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.

Adaptive Phage

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT`s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT`s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.